This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| laetrile | |
|---|---|
| Other names | amygdalin, nitriloside, vitamin B17 |
| Routes of administration | oral, intramuscular (historical) |
| Legal status | Varies by country |
laetrile
Laetrile is a semi-synthetic compound derived from Amygdalin historically promoted as an alternative cancer treatment by figures such as Ernst T. Krebs Jr., Evelyn Lauder, and advocates associated with clinics in Tijuana and Cancún. Proponents linked its use to celebrities and political figures including Steve McQueen, Jackie Gleason, and critics aligned with movements around Christian Science and orthomolecular medicine. Mainstream institutions like the United States Food and Drug Administration, National Cancer Institute, and American Cancer Society examined laetrile amid high-profile legal battles involving persons such as Rex M. Davis and litigation in courts including the United States Court of Appeals for the Ninth Circuit.
Laetrile's lineage traces to traditional remedies from China and 19th-century European use of Prunus dulcis derivatives; it was chemically characterized during investigations at institutions like the University of California, Berkeley and developed commercially by proponents affiliated with entities such as the Rex Research archive and clinics in Mexico City and Tijuana. Public interest surged in the 1950s–1970s through advocacy by figures including Ernst T. Krebs Sr. and Ernst T. Krebs Jr., and through media coverage from outlets like The New York Times and Time (magazine). Regulatory responses involved the Food and Drug Administration's seizures, enforcement actions in the United States District Court for the Southern District of California, and scientific reviews by the National Academy of Sciences and panels convened at the National Institutes of Health. Legal disputes implicated legislators and agencies such as the California State Legislature and the United States Congress in debates over interstate commerce and personal liberty.
Chemically, laetrile is related to the glycoside amygdalin found in seeds of Prunus dulcis (bitter almonds), Prunus armeniaca (apricot), and Prunus persica (peach). Analytical chemistry work at institutions like Harvard University and Massachusetts Institute of Technology examined its hydrolysis to yield benzaldehyde and hydrogen cyanide under enzymatic action by β-glucosidase. Formulations sold as laetrile varied: injectable preparations produced by compounding pharmacies in places like Tijuana and oral tablets marketed by companies linked to Alternative medicine entrepreneurs differed in purity and concentration; manufacturing practices were scrutinized by inspectors from agencies including the United States Pharmacopeia and Food and Drug Administration.
Advocates claimed laetrile's anticancer effect resulted from selective cyanide release within malignant tissues, allegedly due to higher beta-glucosidase activity in tumors and lower levels of rhodanese in cancer cells, thereby causing cytotoxicity preferentially in neoplastic tissue. This hypothesis drew on biochemical concepts explored at laboratories affiliated with Johns Hopkins University and University of Texas MD Anderson Cancer Center. Critics referenced enzymology studies from institutions like Columbia University and University College London demonstrating that cyanide liberation is systemic and not tumor-specific, involving metabolic pathways similar to those characterized by Linus Pauling and researchers in biochemistry at Stanford University.
Clinical evaluations by the National Cancer Institute, systematic reviews in journals such as The New England Journal of Medicine and The Lancet, and randomized and non-randomized trials examined laetrile's efficacy; major studies conducted at centers including Memorial Sloan Kettering Cancer Center and the MD Anderson Cancer Center failed to demonstrate objective anticancer benefits. Case series and anecdotal reports cited by proponents involved patients treated at clinics in Mexico and Mexico City and personalities like Steve McQueen as emblematic cases, but rigorous trials summarized by the Cochrane Collaboration and reviews by the American Cancer Society concluded there was no reliable evidence that laetrile increases survival, reduces tumor burden, or improves quality of life relative to standard oncology treatments such as surgery, chemotherapy regimens developed at Dana-Farber Cancer Institute and radiotherapy protocols from Memorial Sloan Kettering Cancer Center.
Toxicological investigations by laboratories at the Centers for Disease Control and Prevention and chemical pathology units at hospitals including Mayo Clinic documented cyanide poisoning cases after laetrile ingestion, with symptoms reported to poison control centers in cities such as Los Angeles and New York City. Reports to agencies including the Food and Drug Administration and case series published in journals like JAMA described metabolic acidosis, altered consciousness, and fatal outcomes linked to high doses or concomitant dietary factors (e.g., ingestion of almonds or apricot kernels). Clinical toxicology protocols from institutions like Johns Hopkins Hospital emphasize monitoring cyanide biomarkers and supportive care including administration of antidotes such as amyl nitrite and sodium thiosulfate.
Regulatory positions varied: the United States Food and Drug Administration banned interstate distribution of injectable and oral preparations marketed as laetrile in the 1970s and 1980s; litigation in federal courts, including actions in the United States District Court for the Eastern District of California, shaped enforcement. Countries such as Mexico and clinics in Tijuana continued to offer laetrile amidst differing national policies. Professional bodies like the American Medical Association and advisory panels at the National Institutes of Health issued statements discouraging its use. Enforcement involved agencies such as the Federal Bureau of Investigation in cases of fraudulent claims and inspections by the Food and Drug Administration and customs authorities.
Laetrile became emblematic of wider disputes involving proponents from alternative medicine networks, activists associated with groups like Right to Try, and media figures who framed the debate as conflict between patient autonomy and regulatory oversight exemplified by hearings in the United States Congress. Ethical questions engaged bioethicists at institutions like Harvard Medical School and University of Pennsylvania and activists from patient advocacy organizations including Breast Cancer Action and Susan G. Komen for the Cure. Debates overlapped with celebrity advocacy, underground distribution networks in cities such as Los Angeles and New York City, and controversies over informed consent, investigational therapies, and the role of regulatory agencies in protecting public health.
Category:Alternative cancer therapies Category:Plant-derived compounds Category:Controversies in medicine